San Francisco—A host of novel medications
that have been developed with recombinant DNA techniques are offering physicians
new options for treating psoriasis and psoriatic arthritis that cannot be
well controlled by standard therapies. An estimated 30% of the 5.5 million
people of all ages with psoriasis in the United States experience the moderate-to-severe
form of the illness that these new agents are designed to treat.
Lynne Lamberg. A Host of Novel Agents for Treating Psoriasis, Psoriatic Arthritis Stir Interest. JAMA. 2003;289(21):2779–2783. doi:10.1001/jama.289.21.2779